A 3-Arm Randomised Phase II Evaluation of Cediranib in Combination with Weekly Paclitaxel or Olaparib Versus Weekly Paclitaxel Chemotherapy as Second-Line Therapy for Advanced/ Metastatic Endometrial Carcinoma or for disease relapse within 12 months of adjuvant carboplatin-paclitaxel chemotherapy
Phase of Trial: Phase II
Latest Information Update: 23 Jan 2019
At a glance
- Drugs Cediranib (Primary) ; Olaparib (Primary) ; Paclitaxel
- Indications Carcinoma; Endometrial cancer
- Focus Therapeutic Use
- Acronyms COPELIA
- 08 Oct 2018 Recruitment start date for this study is 12/02/2018 while the anticipated recruitment end date is 01/10/2019
- 16 Jan 2018 Status changed from not yet recruiting to recruiting.
- 15 Jan 2018 Status changed from recruiting to not yet recruiting.